Industry: Biomedical Region: France Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
A French company, focusing on innovative therapeutic analysis services such as gene and cell therapy, provides full-process support covering R&D, preclinical, quality control and clinical stages. The company takes molecular biology, immunology and virology as its core technical advantages, and carries out testing and verification according to strict international standards. Its clients include scientific research institutions and biomedical enterprises, and its services cover drug safety, effectiveness and quality evaluation, aiming at accelerating innovative therapy from laboratory to clinical application.
Introduction to core business:
1. Preclinical development
Provide scientific and reliable analysis support for innovative therapeutic products in the early stage of research and development. The company is responsible for establishing and verifying detection methods to evaluate the performance of candidate drugs in vivo and in vitro, such as gene expression, cell transduction efficiency, immune response and potential toxicity.
2. Quality control
In the stage of drug production and release, the company provides all-round quality and safety testing to ensure that the products meet international standards. This part is especially aimed at gene and cell therapy products, DNA/RNA drugs and virus vectors.
3. Clinical trials
This field focuses on sample analysis and treatment monitoring in clinical trials. The company uses a mature bioanalysis platform to detect and count patient samples, which provides a key scientific basis for clinical research.
Cooperation mode:
Seek partners who need gene and cell therapy analysis services in the biomedical field.